InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
June 26, 2023 08:00 ET
|
InspireMD, Inc.
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform ...
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
May 16, 2023 07:00 ET
|
InspireMD, Inc.
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over...
InspireMD Announces Private Placement of Up to $113.6 Million
May 15, 2023 08:00 ET
|
InspireMD, Inc.
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4...
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
May 12, 2023 16:05 ET
|
InspireMD, Inc.
- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
May 05, 2023 08:00 ET
|
InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent...
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
May 01, 2023 08:00 ET
|
InspireMD, Inc.
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system ...
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
April 27, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease...
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
March 30, 2023 07:00 ET
|
InspireMD, Inc.
- 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 - - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD)...
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
March 20, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that...